On July 27, Moderna, Inc. rose 5.15% in regular trading, trading at $56.945/share, with turnover of $43.88 million. The rally reflects a recovery bounce following a 5.07% decline on July 24 triggered by cautious institutional sentiment ahead of the Q2 earnings release scheduled for July 31.

On the catalyst front, Goldman Sachs raised its price target on Moderna from $49 to $67 on July 20, maintaining a Neutral rating, with the new target significantly above the current share price, providing valuation support. Additionally, market expectations for the FDA approval of the company's seasonal influenza vaccine candidate mRNA-1010 continue to build, with the regulatory decision deadline set for August 5. The vaccine previously received a unanimous 9-0 favorable vote from the FDA's advisory committee.

Separately, Jefferies raised its target to $60 from $53 in mid-July, while FactSet consensus target stood at $52.16. The upcoming earnings report carries a consensus EPS estimate of -$1.97, with analysts citing ongoing cost pressures and uncertainty around new product commercialization timelines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)